Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Key Points
In patients with RR-AML, venetoclax combination therapy resulted in responses in 31% of patients and a median OS of 6.1 months.
NPM1 mutations predicted higher response rates; adverse cytogenetics and mutations in TP53, KRAS/NRAS, and SF3B1 predicted worse OS.
Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia
Key Points
The weighted expressions of 7 coding and 3 noncoding genes is strongly associated with relapse in CN-AML patients.
The 10-gene signature is independent from mutations known to associate with outcome in AML patients.
Germline mutations in MDS/AML predisposition disorders
Purpose of review: Recognition of hereditary hematopoietic malignancies impacts patient management as well as health surveillance strategies for the patient and relatives who share the causative DNA variant. In this review, barriers to the diagnosis and management of patients are outlined.
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management"
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors
We compared outcomes in 603 patients with myelodysplastic syndrome (MDS) after HLA-haploidentical relative (n = 176) and HLA-matched unrelated (n = 427) donor hematopoietic cell transplantation (HCT) from 2012 to 2017, using the Center for International Blood and Marrow Transplant Research database. All transplantations used reduced-intensity conditioning regimens.